GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences (GILD) Business News

Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
4:31 AM | Saturday | Sep 26, 2026 Defense World

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

News Thumbnail
4:31 AM | Saturday | Sep 26, 2026 Defense World

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

News Thumbnail
7:15 AM | Friday | Sep 25, 2026 Reuters

Genetic discovery yields clues toward reversal of Alzheimer's brain damage

News Thumbnail
7:06 AM | Friday | Sep 25, 2026 ETF Trends

NTHM's Index Rebalance Puts Thematic Rotation to Work

News Thumbnail
3:15 AM | Friday | Sep 25, 2026 Defense World

Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.

News Thumbnail
12:56 PM | Monday | Sep 21, 2026 Zacks Investment Research

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

News Thumbnail
10:01 AM | Thursday | Sep 17, 2026 Zacks Investment Research

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

News Thumbnail
11:31 AM | Wednesday | Sep 16, 2026 Zacks Investment Research

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

News Thumbnail
8:30 AM | Wednesday | Sep 16, 2026 Business Wire

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

News Thumbnail
11:11 AM | Tuesday | Sep 15, 2026 Reuters

Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean

News Thumbnail
11:10 AM | Tuesday | Sep 15, 2026 Business Wire

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

News Thumbnail

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

Defense World

4:31 AM | Saturday | Sep 26, 2026

news photo
Loading...

Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to

Read full article redirect
4:31 AM | Saturday | Sep 26, 2026

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

Defense World

Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to

Read full article arrow
News Thumbnail
4:31 AM | Saturday | Sep 26, 2026

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

Defense World

Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to

Read full article arrow
News Thumbnail
7:15 AM | Friday | Sep 25, 2026

Genetic discovery yields clues toward reversal of Alzheimer's brain damage

Reuters

Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise ​against a difficult-to-treat form of blood cancer, and an interesting new method for studying cells linked to age-related disorders.

Read full article arrow
News Thumbnail
7:06 AM | Friday | Sep 25, 2026

NTHM's Index Rebalance Puts Thematic Rotation to Work

ETF Trends

The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.

Read full article arrow
News Thumbnail
3:15 AM | Friday | Sep 25, 2026

Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.

Defense World

Envestnet Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,749,512 shares of the biopharmaceutical company's stock after selling 109,500 shares during the period.
Envestnet Asset Management Inc. owned approximately

Read full article arrow
News Thumbnail
12:56 PM | Monday | Sep 21, 2026

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Zacks Investment Research

Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.

Read full article arrow
News Thumbnail
10:01 AM | Thursday | Sep 17, 2026

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
11:31 AM | Wednesday | Sep 16, 2026

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

Zacks Investment Research

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Sep 16, 2026

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.

Read full article arrow
News Thumbnail
11:11 AM | Tuesday | Sep 15, 2026

Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean

Reuters

U.S. drugmaker Gilead Sciences said on Tuesday it had reached an agreement with the Pan American Health Organization to ​widen access to its HIV prevention drug across Latin ‌America and the Caribbean, as the regions seek to curb new infections.

Read full article arrow
News Thumbnail
11:10 AM | Tuesday | Sep 15, 2026

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO's Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led effor.

Read full article arrow
News Thumbnail